Find a Company:
U.S. Analyst Ratings (NYSE and NASDAQ)
All U.S. Ratings
Price Target Changes
Canadian Analyst Ratings (TSE and TSV)
U.K. Analyst Ratings (LSE)
Australian Analyst Ratings (ASX)
Lookup Company Ratings
Free Ratings Newsletter
ARN Daily Premium ($)
Stock Ratings App
Free Earnings Newsletter
CER Wire Premium ($)
Lookup Company Earnings
NanoString Technologies Company Profile (NASDAQ:NSTG)
Consensus Ratings for NanoString Technologies (NASDAQ:NSTG)
The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
1 Hold Rating(s), 2 Buy Rating(s)
Buy (Score: 2.67)
Consensus Price Target:
$18.33 8.10% downside)
Analysts' Ratings History for NanoString Technologies (NASDAQ:NSTG)
All Ratings For This Stock
Only the Most Recent Rating From Each Brokerage
Boost Price Target
$20.00 -> $23.00
Overweight -> Equal Weight
Robert W. Baird
Neutral -> Outperform
$12.00 -> $18.00
JPMorgan Chase & Co.
Robert W. Baird
JPMorgan Chase & Co.
(Data available from 3/9/2012 forward)
Earnings History for NanoString Technologies (NASDAQ:NSTG)
(Data available from 1/1/2011 forward)
Dividend History for NanoString Technologies (NASDAQ:NSTG)
No dividend announcements for this company have been tracked by Analyst Ratings Network
Insider Trading History for NanoString Technologies (NASDAQ:NSTG)
Number of Shares
Average Share Price
Lifesciences Ii L.P. Clarus
(Data available from 1/1/2013 forward)
About NanoString Technologies
NanoString Technologies, Inc. develops, manufactures and sells products, which unlock clinically actionable genomic information from minute amounts of tissue. The Company's nCounter Analysis System directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company market systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of disease. As of May 20, 2013, it had an installed base of more than 130 systems. Its nCounter Analysis System enables research on a scale appropriate for pathway-based biology by digitally quantifying the activity of up to 800 genes simultaneously in a single experiment. Prosigna, its molecular diagnostic test, is based on a collection of 50 genes known as the PAM50 gene signature.
NanoString Technologies Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
NanoString Technologies to Participate in the Cowen 34th Annual Health Care Conference
NanoString Technologies Launches Commercial Reagents to Enable Laboratories to Rapidly Develop Tests From ...
Study Confirms Ability of the Prosigna Assay to Assess Risk of Late Distant Recurrence in Postmenopausal Women With ...
NanoString To Present At Cowen Health Care Conference; Webcast At 11:20 AM ET
Industry, Sector and Symbol:
50 Day Moving Average:
200 Day Moving Average:
Current Quarter EPS Consensus Estimate:
View NSTG on Google Finance
View NSTG on Yahoo Finance
View NSTG's Company Profile on Reuters
Search for NanoString Technologies Inc on Google
NanoString Technologies (NASDAQ:NSTG) Chart for Sunday, March, 9, 2014
(Chart Provided by
© Analyst Ratings Network 2010-2014. All rights reserved.
Terms and Conditions
Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security.